Sequential Use of Second-Generation Tyrosine Kinase Inhibitor Treatment and Intensive Chemotherapy Induced Long-Term Complete Molecular Response in Imatinib-Resistant CML Patient Presenting as a Myeloid Blast Crisis.

Autor:	Tsuji, Masaaki, Uchiyama, Tatsuki, Mizumoto, Chisaki, Takeoka, Tomoharu, Tomo, Kenjiro, Ohno, Tatsuharu
Předmět:	MYELOID leukemia PROTEIN-tyrosine kinase inhibitors IMATINIB COMBINATION drug therapy DASATINIB PATIENTS
Zdroj:	Case Reports in Hematology; 12/17/2017, p1-4, 4p
Abstrakt:	Myeloid blast crisis of chronic myeloid leukemia (CML-MBC) is rarely seen at presentation and has a poor prognosis. There is no standard therapy for CML-MBC. It is often difficult to distinguish CML-MBC from acute myeloid leukemia expressing the Philadelphia chromosome (Ph+ AML). We present a case in which CML-MBC was seen at the initial presentation in a 75-year-old male. He was treated with conventional AML-directed chemotherapy followed by imatinib mesylate monotherapy, which failed to induce response. However, he achieved long-term complete molecular response after combination therapy involving dasatinib, a second-generation tyrosine kinase inhibitor, and conventional chemotherapy. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu